Intravenous Infusions (XGHA:IIL) Net Margin %: 0.00% (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Intravenous Infusions Net Margin %?

Intravenous Infusions XGHA:IIL +8.86% Net Margin % is 0.00% as of . 20. Among 961 Drug Manufacturers companies, Intravenous Infusions ranks worse than 104058.17% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Intravenous Infusions's Net Income for the six months ended in . 20 was GHS0.00 Mil. Intravenous Infusions's Revenue for the six months ended in . 20 was GHS0.00 Mil. Therefore, Intravenous Infusions's net margin for the quarter that ended in . 20 was 0.00%.

The historical rank and industry rank for Intravenous Infusions's Net Margin % or its related term are showing as below:


XGHA:IIL's Net Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 5.47
* Ranked among companies with meaningful Net Margin % only.

Intravenous Infusions  (XGHA:IIL) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Intravenous Infusions Net Margin % Related Terms

Intravenous Infusions Net Margin % Historical Data

* Premium members only.

The historical data trend for Intravenous Infusions's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Intravenous Infusions Net Margin % Chart

Intravenous Infusions Annual Data
Trend
Net Margin %

Intravenous Infusions Semi-Annual Data
Net Margin %

XGHA:IIL vs PTLF, PCYN, YBAO: Net Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Intravenous Infusions's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Intravenous Infusions Net Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Intravenous Infusions's Net Margin % distribution charts can be found below:

* The bar in red indicates where Intravenous Infusions's Net Margin % falls into.


Intravenous Infusions Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Intravenous Infusions's Net Margin for the fiscal year that ended in . 20 is calculated as

Net Margin=Net Income (A: . 20 )/Revenue (A: . 20 )
=/
= %

Intravenous Infusions's Net Margin for the quarter that ended in . 20 is calculated as

Net Margin=Net Income (Q: . 20 )/Revenue (Q: . 20 )
=/
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
Intravenous Infusions (XGHA:IIL) has a Net Margin % of 0.00% as of . 20. Net margin is the ratio of total net income to net sales. View historical data on Intravenous Infusions and its competitors. According to the industry distribution chart, Intravenous Infusions ranks #999999 out of 961 companies in the Drug Manufacturers industry.
Is Intravenous Infusions' Net Margin % too high?
Intravenous Infusions' current Net Margin % is 0.00%. Based on the distribution chart, Intravenous Infusions ranks #999999 out of 961 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Intravenous Infusions' Net Margin % compare to PTLF and PCYN?
According to the Drug Manufacturers industry distribution chart, Intravenous Infusions ranks #999999 out of 961 companies for Net Margin %. This places Intravenous Infusions in the lower half of its industry. The industry median Net Margin % is 5.47. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.47, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Intravenous Infusions and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Intravenous Infusions's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intravenous Infusions stock overvalued right now?
Intravenous Infusions (XGHA:IIL) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Intravenous Infusions (XGHA:IIL), the current Net Margin % is 0.00% as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Intravenous Infusions Business Description

Address Plot 4/7 Blk L, P.O Box KF 63, Effiduase-Koforidua, GHA
Intravenous Infusions Ltd engages in the production of intravenous infusion and small-volume injectables for therapeutic purposes. The product categories are IV fluids, giving sets, and small-volume injectables. The company earns a majority of its revenue from IV fluids. Some of the IV fluids are sodium chloride solutions, dextrose solutions, dextrose saline solutions, and dextran solutions. Small-volume injectables include pethidine injection, magnesium sulphate injection, and quinine injection. Giving sets include plain giving sets, and blood giving sets.